Literature DB >> 27409727

Relationships between serum brain-derived neurotrophic factor, plasma catecholamine metabolites, cytokines, cognitive function and clinical symptoms in Japanese patients with chronic schizophrenia treated with atypical antipsychotic monotherapy.

Hikaru Hori1, Reiji Yoshimura1, Asuka Katsuki1, Kiyokazu Atake1, Ryohei Igata1, Yuki Konishi1, Jun Nakamura1.   

Abstract

OBJECTIVES: Catecholamines, brain-derived neurotrophic factor (BDNF) and cytokines may be involved in the pathophysiology of schizophrenia. The aim of this study was to examine the associations between serum BDNF levels, plasma catecholamine metablolites, cytokines and the cognitive functions of patients with schizophrenia treated with atypical antipsychotic monotherapy.
METHODS: One hundred and forty-six patients with schizophrenia and 51 age- and sex-matched healthy controls were examined for peripheral biological markers and neurocognitive test.
RESULTS: There were positive correlations between serum BDNF levels and scores for verbal memory and attention and processing speed as well as between serum BDNF levels and negative symptoms. Furthermore, there was a negative correlation between the plasma homovanillic acid (HVA) level and motor function and a positive correlation between the plasma 3-methoxy-4-hydroxyphenylglycol (MHPG) level and attention and processing speed. There were no significant correlations between interleukin-6 or tumour necrosis factor alpha and cognitive function. Moreover, there were no significant correlations between the plasma levels of HVA, MHPG, cytokines and clinical symptoms.
CONCLUSIONS: Serum BDNF levels are positively related to the impairment of verbal memory and attention, plasma HVA levels are positively related to motor function, and plasma MHPG levels are positively related to attention in patients with schizophrenia.

Entities:  

Keywords:  Schizophrenia; brain-derived neurotrophic factor; catecholamine metabolites; cognitive function; cytokines

Mesh:

Substances:

Year:  2016        PMID: 27409727     DOI: 10.1080/15622975.2016.1212172

Source DB:  PubMed          Journal:  World J Biol Psychiatry        ISSN: 1562-2975            Impact factor:   4.132


  18 in total

Review 1.  Brain-Derived Neurotrophic Factor Expression in Individuals With Schizophrenia and Healthy Aging: Testing the Accelerated Aging Hypothesis of Schizophrenia.

Authors:  Farhana Islam; Benoit H Mulsant; Aristotle N Voineskos; Tarek K Rajji
Journal:  Curr Psychiatry Rep       Date:  2017-07       Impact factor: 5.285

2.  Relationship of Interferon-γ to Cognitive Function in Midlife Women with Schizophrenia.

Authors:  Kathleen E Wilson; Haley Demyanovich; Leah H Rubin; Heidi J Wehring; Catherine Kilday; Deanna L Kelly
Journal:  Psychiatr Q       Date:  2018-12

3.  Immunoglobulin genotypes and cognitive functions in schizophrenia.

Authors:  Janardan P Pandey; Aryan M Namboodiri; Paul J Nietert; Reiji Yoshimura; Hikaru Hori
Journal:  Immunogenetics       Date:  2017-09-22       Impact factor: 2.846

4.  The relationship between immune and cognitive dysfunction in mood and psychotic disorder: a systematic review and a meta-analysis.

Authors:  M Morrens; C Overloop; V Coppens; E Loots; M Van Den Noortgate; S Vandenameele; M Leboyer; L De Picker
Journal:  Mol Psychiatry       Date:  2022-04-28       Impact factor: 15.992

5.  Inflammation, hippocampal volume, and cognition in schizophrenia: results from the Northern Finland Birth Cohort 1966.

Authors:  Brian J Miller; Karl-Heinz Herzig; Jari Jokelainen; Toni Karhu; Sirkka Keinänen-Kiukaanniemi; Marjo-Riitta Järvelin; Juha Veijola; Heimo Viinamäki; Erika Jääskeläinen; Matti Isohanni; Markku Timonen
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2020-05-07       Impact factor: 5.270

6.  Peripheral immune markers and antipsychotic non-response in psychosis.

Authors:  Daniela Enache; Naghmeh Nikkheslat; Dina Fathalla; B Paul Morgan; Shôn Lewis; Richard Drake; Bill Deakin; James Walters; Stephen M Lawrie; Alice Egerton; James H MacCabe; Valeria Mondelli
Journal:  Schizophr Res       Date:  2021-03-02       Impact factor: 4.662

7.  Blood Biomarkers Predict the Cognitive Effects of Aripiprazole in Patients with Acute Schizophrenia.

Authors:  Hikaru Hori; Reiji Yoshimura; Asuka Katsuki; Kiyokazu Atake; Ryohei Igata; Yuki Konishi; Hiroki Beppu; Hirotaka Tominaga
Journal:  Int J Mol Sci       Date:  2017-03-06       Impact factor: 5.923

Review 8.  Brain-Derived Neurotrophic Factor: A Key Molecule for Memory in the Healthy and the Pathological Brain.

Authors:  Magdalena Miranda; Juan Facundo Morici; María Belén Zanoni; Pedro Bekinschtein
Journal:  Front Cell Neurosci       Date:  2019-08-07       Impact factor: 5.505

Review 9.  BDNF as a Biomarker of Cognition in Schizophrenia/Psychosis: An Updated Review.

Authors:  Rodrigo R Nieto; Andrea Carrasco; Sebastian Corral; Rolando Castillo; Pablo A Gaspar; M Leonor Bustamante; Hernan Silva
Journal:  Front Psychiatry       Date:  2021-06-16       Impact factor: 4.157

10.  The Impact of Aging, Psychotic Symptoms, Medication, and Brain-Derived Neurotrophic Factor on Cognitive Impairment in Japanese Chronic Schizophrenia Patients.

Authors:  Kiyokazu Atake; Tomoyuki Nakamura; Nobuhisa Ueda; Hikaru Hori; Asuka Katsuki; Reiji Yoshimura
Journal:  Front Psychiatry       Date:  2018-05-29       Impact factor: 4.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.